This article is more than 5 years old. Information may no longer be current.

Leiters, Mobius Therapeutics partner to market Mitosol

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Leiters and Mobius Therapeutics have entered into a national sales and marketing agreement for the only FDA-approved mitomycin C formulation with an ophthalmic indication, according to a press release.

Mitosol (mitomycin for solution 0.2 mg/vial) is available as part of an ophthalmic use kit, which also includes accessories for safe and compliant acquisition, storage and handling, the release said.

The agreement allows Mobius to supply Mitosol in order to minimize supply disruption.

“We are excited to partner with Mobius Therapeutics to ensure our ophthalmic customers have access to the high-quality medicines they need for their patients,” Robin Smith Hoke, Leiters CEO, said in the release.